Exelixis, Inc. and Catalent today announced a partnership under which Catalent will develop multiple ADCs for Exelixis using Catalent’s proprietary SMARTag® technology.

Catalent today announced that it is investing $50 million to install an additional high-speed vial filling line at its Bloomington, Indiana, facility.

Catalent today announced that two Catalent Biologics experts will present at the upcoming 16th Annual PEGS Boston Virtual Conference & Expo, taking place between Aug. 31 – September 4, 2020.

Catalent Cell & Gene Therapy will provide drug substance manufacturing for the University of Oxford’s adenovirus vector-based vaccine at Catalent’s Harmans, Maryland gene therapy manufacturing facility.

Catalent today announced it will present at the upcoming World Orphan Drug Congress Annual Meeting, which will take place virtually on Aug. 24 – 26, 2020.

Catalent today announced that Paul Ingram, Ph.D., Global Director, Strategic Development and Innovation, will present at the upcoming conference, ‘Clinical Trial Supply Forum’.

Catalent today announced that it was approved by the U.S. FDA to produce commercial drug substance intermediate for AveXis’ spinal muscular atrophy gene therapy.

Catalent today announced that it will expand its Argentinian site in Loma Hermosa, Buenos Aires. The expansion will be segregated and designed to handle cytotoxic and highly active products for prescription softgel manufacturing.

Catalent will support the development, manufacturing, and clinical supply of Editas Medicine’s portfolio of in vivo CRISPR medicines and engineered cell medicines.